Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AAN | American Academy of Neurology |
| ACTH | Adrenocorticotropic hormone |
| AED | Antiepileptic drug |
| AES | American Epilepsy Society |
| AHFS | American Hospital Formulary Service |
| ASM | Antiseizure medication |
| ASO | Antisense oligonucleotide |
| ASSR | Auditory steady-state response |
| AUC | Area under the concentration-time curve |
| BSFC | Burden Scale for Family Caregivers |
| BTD | Breakthrough Therapy designation |
| CgGI-I | Caregiver Global Impression of Improvement |
| CGI-I | Clinical Global Impression of Improvement |
| CNS | Central nervous system |
| CYP | Cytochrome P450 |
| DEE | Developmental and epileptic encephalopathy |
| ECG | Electrocardiogram |
| EEG | Electroencephalography |
| EMA | European Medicines Agency |
| EQ-5D | EuroQol 5-Dimension questionnaire |
| FDA | Food and Drug Administration |
| G/J | Gastrostomy/jejunostomy |
| GOF | Gain of function |
| GSV | Growth scale value |
| HADS | Hospital Anxiety and Depression Scale |
| IEC | International Epilepsy Congress |
| ITT | Intention to treat |
| IV | Intravenous |
| LOF | Loss of function |
| MES | Maximal electroshock seizure |
| NDA | New Drug Application |
| NDDwGE | Neurodevelopmental disorder with generalized epilepsy |
| ODD | Orphan Drug Designation |
| OLE | Open-label extension |
| OXC | Oxcarbazepine |
| PD | Pharmacodynamics |
| PDUFA | Prescription Drug User Fee Act |
| PK | Pharmacokinetics |
| PRAX-562 | Development code for relutrigine |
| QD | Once daily |
| QI-Disability | Quality of Life Inventory-Disability |
| QoL | Quality of life |
| REMS | Risk Evaluation and Mitigation Strategy |
| SAE | Serious adverse event |
| SCB | Sodium channel blocker |
| SCN2A | Sodium voltage-gated channel alpha subunit 2 gene |
| SCN8A | Sodium voltage-gated channel alpha subunit 8 gene |
| SeL(F)IE | Self-limited familial or nonfamilial infantile epilepsy |
| sLMA | Spontaneous locomotor activity |
| TEAE | Treatment-emergent adverse event |
| UK | United Kingdom |
| US | United States |
| VABS | Vineland Adaptive Behavior Scales |